- Conditions
- Precocious, Leuprolide Acetate, Luteinizing Hormone (LH), Gonadotrophin-releasing Hormone Agonist (GnRHa), Tanner Staging, Depot Formulation, Suppression of LH, Central Precocious Puberty (CPP), Gonadotrophin-releasing Hormone (GnRH), Lupron, GnRH Analog, Pediatrics Central Precocious Puberty
- Interventions
- Leuprolide Acetate 3 Month Depot
- Drug
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Industry
- Eligibility
- Not listed
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Long Beach, California • Los Angeles, California + 13 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1537–1560
of 16,007
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Uveitic Cystoid Macular Edema
- Interventions
- ranibizumab
- Drug
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 2
- States / cities
- Miami, Florida • Palm Beach Gardens, Florida
- Conditions
- Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Myelodysplastic Syndromes, Multiple Myeloma, Non-Hodgkins Lymphoma, Hodgkins Disease, Peripheral T-cell Lymphoma
- Interventions
- Pentostatin, Total-body irradiation (TBI), Cyclosporine A (CsA), Mycophenolate Mofetil (MMF), G-CSF
- Drug · Radiation
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years to 75 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2008
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Amyloidosis
- Interventions
- Melphalan, Autologous Stem Cell Transplantation
- Drug · Procedure
- Lead sponsor
- Herbert Irving Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2004
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Lung Cancer
- Interventions
- Tirzepatide
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Alzheimer's Disease, Mild Cognitive Impairment
- Interventions
- Saline, Insulin detemir, Insulin
- Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 50 Years to 89 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 2
- States / cities
- Winston-Salem, North Carolina • Tacoma, Washington
- Conditions
- Metastatic Melanoma, Stage III Melanoma, Stage IV Melanoma
- Interventions
- Indoximod, Ipilimumab, Nivolumab, Pembrolizumab
- Drug
- Lead sponsor
- NewLink Genetics Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 131 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 6
- States / cities
- Augusta, Georgia • Iowa City, Iowa • Rochester, Minnesota + 3 more
- Conditions
- Melanoma Metastatic
- Interventions
- Interleukin-2
- Drug
- Lead sponsor
- Western Regional Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Goodyear, Arizona
- Conditions
- Refractory Plasma Cell Myeloma
- Interventions
- Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Laboratory Biomarker Analysis
- Drug · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- Brain Tumor, Central Nervous System Tumor
- Interventions
- filgrastim, carboplatin, cyclophosphamide, etoposide, vincristine sulfate, radiation therapy, Mesna, therapeutic conventional surgery
- Biological · Drug · Radiation + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 378 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2016
- U.S. locations
- 140
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 118 more
- Conditions
- Transient Insomnia
- Interventions
- Gabapentin, Placebo
- Drug
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 256 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 3
- States / cities
- Glendale, California • San Diego, California • Overland Park, Kansas
- Conditions
- Stroke
- Interventions
- D-cycloserine + distributed treatment, D-cycloserine + condensed treatment, Placebo + distributed treatment, Placebo + condensed treatment
- Drug · Behavioral
- Lead sponsor
- US Department of Veterans Affairs
- Federal
- Eligibility
- 20 Years to 80 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Leukemia, Precursor b-Cell Lymphoblastic Leukemia-Lymphoma, ACUTE LYMPHOBLASTIC LEUKEMIA
- Interventions
- inotuzumab ozogamicin-dose level 2, Inotuzumab ozogamicin-dose level 1
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 1 more
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS), Platinum-resistant Ovarian Cancer (PROC), Hepatocellular Carcinoma (HCC), Colorectal Cancer (CRC), HER2 Negative Breast Cancer, Cutaneous Melanoma, Renal Cell Carcinoma (RCC)
- Interventions
- GI-102 subcutaneous (SC), GI-102, doxorubicin, paclitaxel, bevacizumab, eribulin, trastuzumab deruxtecan (T-DXd), pembrolizumab
- Drug
- Lead sponsor
- GI Innovation, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 358 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 5
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota + 2 more
- Conditions
- Suicidal Ideation
- Interventions
- Ketamine, Midazolam
- Drug
- Lead sponsor
- James Murrough
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Solid Tumors
- Interventions
- Relacorilant with nab-paclitaxel
- Drug
- Lead sponsor
- Corcept Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 4
- States / cities
- Scottsdale, Arizona • San Francisco, California • Chicago, Illinois + 1 more
- Conditions
- Breast Cancer
- Interventions
- filgrastim, carboplatin, cyclophosphamide, doxorubicin hydrochloride, paclitaxel, thiotepa, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- Up to 60 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2013
- U.S. locations
- 2
- States / cities
- Phoenix, Arizona • Duarte, California
- Conditions
- Myeloma, Stem Cell Transplantation
- Interventions
- Lenalidomide, Melphalan, Stem Cell Infusion
- Drug · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Metastatic Pancreatic Cancer
- Interventions
- cetuximab, bevacizumab, gemcitabine
- Biological · Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 16
- States / cities
- Jonesboro, Arkansas • San Francisco, California • Stamford, Connecticut + 12 more
- Conditions
- Wrinkle
- Interventions
- Botulinum toxin type A
- Drug
- Lead sponsor
- Global Aesthetics LLC
- Other
- Eligibility
- 20 Years to 65 Years
- Timeline
- 2024 – 2027
- U.S. locations
- 2
- States / cities
- Cisco, Texas • Lubbock, Texas
- Conditions
- Child Development, Cannabis Use
- Interventions
- Placebo, Choline
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 140 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Metabolic Diseases
- Interventions
- Oral Glucose Tolerance Test, Kisspeptin, Placebo
- Diagnostic Test · Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Melanoma
- Interventions
- Mocetinostat Induction Phase + Ipilimumab + Nivolumab, Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Psoriasis
- Interventions
- Etanercept
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 38 more